Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YL 202

Next Previous
Drug Profile

YL 202

Alternative Names: BNT-326; YL-202

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediLink Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Solid tumours
  • Phase I HER2 negative breast cancer; Non-small cell lung cancer

Most Recent Events

  • 02 Sep 2025 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in China (IV) (NCT07169994)
  • 08 Aug 2025 BioNTech SE plans to initiate a phase Ib/II trial for Non-small Cell Lung Cancer (Late-stage disease, In combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) (IV) (NCT07111520)
  • 04 Aug 2025 BioNTech plans a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Monotherapy, Combination therapy, Inoperable/Unresectable, Second line therapy or greater) (IV, Infusion), in 2025 (NCT07070232)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top